Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
9 results loaded, newest first. End of these results.
By Chris WackMerck said it saw positive topline results for its Phase 2b/3 trial for remigromig in adults with diabetic macular edema.The pharmaceutical company said the trial, the first of two Phase 2b/3 trials evaluating the safety and efficacy of remigromig met its primary endpoint.Remigromig is…
MRK MERCK'S REMIGROMIG MEETS PRIMARY ENDPOINT IN DME TRIAL
Merck reported topline results from the pivotal Phase 2b/3 BRUNELLO trial of remigromig in adults with diabetic macular edema. Year-one data will be presented Oct. 10 at the American Academy of Ophthalmology Annual Meeting. Both remigromig doses met the primary goal, matching ranibizumab on vision outcomes over 52 week
Merck said remigromig met the primary endpoint of non-inferiority to 0.5 mg ranibizumab in BCVA at 52 weeks in the pivotal Phase 2b/3 BRUNELLO DME trial; higher rates of PDR, vitreous hemorrhage, and AE-related discontinuations were seen vs ranibizumab.Material DetailsContext by AI AnalystThis is a…
MRK keytruda® (pembrolizumab) as monotherapy significantly improved progression-free survival (pfs) in certain patients with advanced or recurrent endometrial cancer with mismatch repair deficient (dmmr) tumors compared to chemotherapy Merck & Co - phase 3 keynote-c93 trial meets primary endpoint of progression-free su
MRK's Phase 3 ATLAS-UC induction-only study met its primary endpoint
Merk's Phase 3 ATLAS-UC study of Tulisokibart meets primary endpoint of clinical remission in patients with moderately to severely active UC
Merck's Tulisokibart met primary and secondary endpoints
Merck's Tulisokibart meets primary and key secondary endpoints in Phase 3 ATLAS-UC induction-only study for ulcerative colitis